London-based venture fund investing in advanced therapies
4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.
4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.
The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.
For more information, please visit www.4biocapital.com
Biotech, Venture Capital, Private Equity, and Non-discretionary advice
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
GSK Pharmaceutical, Pharmaceutical Manufacturing | GSK Pharmaceutical, Pharmaceutical Manufacturing | Other 17 Mar 2024 | | |
2150 Venture Capital and Private Equity Principals | 2150 Venture Capital and Private Equity Principals | Other 31 Oct 2023 | | |
Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 31 Aug 2023 | | |
Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 23 Dec 2022 | | |
Estimeo Consulting, Information Services | Estimeo Consulting, Information Services | Other 19 Sep 2022 | | |
Financial Times Media, Newspaper Publishing | Financial Times Media, Newspaper Publishing | Other 3 Jan 2024 | |